Liver biopsy†

Биопсия печени
Don C. Rockey, Stephen Hugh Caldwell, Zachary D Goodman, Rendon C. Nelson, Alastair D. Smith
2008-11-20

AASLD practice guidelineshepatitis B (HBV) and hepatitis C (HCV)histological assessmentliver biopsynonalcoholic fatty liver disease (NAFLD)
This position paper has been approved by the AASLD and represents the position of the association. These recommendations provide a data-supported approach. They are based on the following: (1) formal review and analysis of the recently published world literature on the topic; (2) American College of Physicians Manual for Assessing Health Practices and Designing Practice Guidelines1; (3) guideline policies, including the AASLD Policy on the Development and Use of Practice Guidelines and the American Gastroenterological Association Policy Statement on Guidelines2; and (4) the experience of the authors in the specified topic. Intended for use by physicians, these recommendations suggest preferred approaches to the diagnostic, therapeutic, and preventive aspects of care. They are intended to be flexible, in contrast to standards of care, which are inflexible policies to be followed in every case. Specific recommendations are based on relevant published information. To more fully characterize the quality of evidence supporting recommendations, the Practice Guidelines Committee of the AASLD requires a Class (reflecting benefit versus risk) and Level (assessing strength or certainty) of Evidence to be assigned and reported with each recommendation (Table 1, adapted from the American College of Cardiology and the American Heart Association Practice Guidelines3).4 AASLD, American Association for the Study of Liver Diseases; AIH, autoimmune hepatitis; ALF, acute liver failure; ALT, alanine aminotransferase; ANA, antinuclear antibody; CT, computed tomography; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HVPG, hepatic venous pressure gradient; IgG, immunoglobulin G; INR, international normalized ratio; NAFLD, nonalcoholic fatty liver disease; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; PT, prothrombin time; US, ultrasound. Histological assessment of the liver, and thus, liver biopsy, is a cornerstone in the evaluation and management of patients with liver disease and has long been considered to be an integral component of the clinician's diagnostic armamentarium. Although sensitive and relatively accurate blood tests used to detect and diagnose liver disease have now become widely available, it is likely that liver biopsy will remain a valuable diagnostic tool. Although histological evaluation of the liver has become important in assessing prognosis and in tailoring treatment, noninvasive techniques (i.e., imaging, blood tests) may replace use of liver histology in this setting, particularly with regard to assessment of the severity of liver fibrosis.5, 6 Several techniques may be used to obtain liver tissue; a table including/defining specific terms has been provided in an effort to standardize terminology (Table 2). All liver biopsy techniques require specific training so as to ensure appropriate-sized specimen retrieval and the lowest rate of complications. Although liver biopsy is often essential in the management of patients with liver disease, physicians and patients may find it to be a difficult undertaking because of the associated risks. The purpose of this practice guideline is to summarize the current practice of liver biopsy and make recommendations about its performance. This guideline deals exclusively with liver biopsy as it relates to adult liver disease. Historically, liver biopsy was used almost exclusively as a diagnostic tool.7, 8 However, as the result not only of new natural history data and the introduction of many new therapies for patients with liver disease, liver biopsy and histological assessment of the liver has now taken on an important role in clinical management. Therefore, as of 2009, liver biopsy currently has three major roles: (1) for diagnosis, (2) for assessment of prognosis (disease staging), and/or (3) to assist in making therapeutic management decisions. For many diseases, clinical and/or blood-based tests suffice to establish a diagnosis (typical examples include hepatitis B [HBV] or hepatitis C virus [HCV] infection). Nonetheless, liver biopsy is often a critical component in establishing the diagnosis of many (other) forms of liver disease. Although histological assessment alone may be able to make a diagnosis on occasion (i.e., a florid duct lesion in primary biliary cirrhosis [PBC]), liver histology is typically and most appropriately considered in conjunction with the full gamut of clinical and laboratory data. Acute and chronic hepatitis, cholestatic disorders, fatty liver disease, vascular diseases, infiltrative or storage diseases, some infectious and granulomatous diseases, and other disorders may be associated with characteristic histological abnormalities that are helpful in diagnosis.9 Liver biopsy is particularly useful in patients with atypical clinical features. For example, liver histology can help distinguish between autoimmune hepatitis (AIH) and nonalcoholic fatty liver disease (NAFLD) in an obese patient with elevated levels of alanine aminotransferase (ALT), raised immunoglobulin G concentration (IgG), and/or a positive antinuclear antibody (ANA) titer. Liver histology may also be very helpful in patients with coexisting disorders such as steatosis and HCV or hemochromatosis10, 11 or an "overlap" syndrome of PBC with AIH.12 It is likely that liver biopsy will always play a role in the management of the patient with a diagnostic dilemma. This includes the patient with abnormal liver tests of unknown etiology (see below) or the patient in whom a specific liver disease has been considered, but has not yet been confirmed. Examples include patients with a variety of possible diseases, including, but not limited to hereditary disorders such as Wilson disease, alpha-1-antitrypsin disease, glycogen storage diseases, tyrosinemia, Niemann-Pick disease, amyloidosis, and others.13-26 Liver histology may also be helpful diagnostically in patients with apparent systemic diseases in which the liver appears to be involved. Microscopic examination of the liver in patients with suspected hereditary hemorrhagic telangiectasia is rarely necessary, and should probably be performed via the transvenous route, concomitant with measurement of the portosystemic pressure gradient.15 Liver histology may provide important diagnostic information in patients with acute liver failure (ALF).27 For example, liver biopsy is helpful in making a specific diagnosis in specific settings (e.g., herpes virus infection, Wilson disease, AIH, and malignancy),27, 28 which in turn may guide more specific therapy. Liver histology in patients with hepatomegaly or apparent diffuse disease may help establish a diagnosis, but whether it is clinically useful or cost effective is unknown. Examples of diffuse diseases include amyloidosis,29, 30 granulomatous hepatitis caused by any of a number of processes, and a host of other miscellaneous disorders. A further important use of liver biopsy is in assessing disease severity, notably fibrosis, which, as a precursor to cirrhosis, may predict the emergence of complications of portal hypertension and also liver-related morbidity and mortality. Evidence in the area of HCV emphasizes the role of fibrosis assessment in determining prognosis. For example, alcohol consumption, increased hepatic iron concentration, and/or hepatic steatosis, all of which are associated with more rapid fibrosis progression in patients with chronic HCV,10, 31-33 are currently assessed best by histology.34 Further, specific evidence links fibrosis and prognosis; an example of this logical relationship is that in patients with HCV infection after liver transplantation, mortality was increased in those with advanced compared to minimal fibrosis.35 Also, progression of NAFLD and eventual liver-related mortality appear to be related to the initial fibrosis stage.36 Evidence that fibrosis assessment is important in prognosis also exists in PBC; in a long-term cohort study of 160 patients with PBC, for every stage increase of fibrosis identified (on a 1–4 point fibrosis scale) on initial liver biopsy, there was a twofold increase in future complications or death (relative risk 2.4; 95% confidence interval [CI]: 1.6–3.6).37 In cases of genetic hemochromatosis, survival in patients without cirrhosis is similar to the normal control population, while mortality in those with advanced fibrosis/cirrhosis is significantly increased38 and patients with cirrhosis are at increased risk of hepatocellular cancer (HCC),38 and should be screened. Liver histology in patients with AIH may also provide prognostic information; the overall outcome for those with cirrhosis appears to be poorer than that for those without cirrhosis.39 Finally, patients with fibrosis regression may actually be protected from developing clinical complications.40 Thus, accurate assessment of liver fibrosis by histological analysis clearly provides important prognostic information. Assessment of liver histology may be particularly beneficial in patients with human immunodeficiency virus and HCV who have persistently normal ALT levels, because these patients may have significant fibrosis, which may be of prognostic importance. This allows the clinician to determine the extent of liver fibrosis and, consequently, to assess suitability for treatment.41 Currently, liver biopsy is used more than ever to develop treatment strategies. As previously emphasized, this has evolved because of the many new therapies available for patients with a variety of liver diseases. Not only can a treatment plan be instituted in a patient after a specific diagnosis is made (i.e., steroids in the setting of AIH), but among those with established liver disease, treatment may be predicated on the specific histological lesion. In the latter circumstance, therapy is usually directed at the patient with a more advanced histological stage. For example, histological analysis of the liver in patients with HCV provides information about the grade (degree of inflammation), which in turn presumably reflects to what extent the liver disease injury remains ongoing. In patients with chronic HCV-induced liver disease, treatment is often advocated for those with at least moderate to severe stages of fibrosis, but may be withheld when fibrosis is minimal or absent.42 Liver histology is also commonly used in disease monitoring of patients with AIH. First, the portal plasma cell score (a measure of portal-based plasma cell infiltrate) may predict relapse,43 and second, liver biopsy is often obtained prior to steroid dose reduction and/or discontinuation of immunosuppressive therapy altogether because the incidence of relapse is substantial in patients with evidence of residual interface hepatitis.44 Finally, there is evidence that patients with PBC with advanced fibrosis at diagnosis may respond less well to ursodeoxycholic acid than do patients with minimal or mild fibrosis, thus placing them at risk of more rapid disease progression and premature death/requirement for liver transplantation.45 For further information on the role of histological analysis in the management of individual liver diseases, please see guidelines for HCV,46 HBV,47 hemochromatosis,48 PBC,49 AIH,44 and Wilson disease.50 The diseases and situations in which liver biopsy may be indicated are listed in Tables 3 and 4. It is important to emphasize that the role of histological analysis of the liver in the management of patients with liver disease is likely to evolve over time, particularly as noninvasive modalities for assessment of fibrosis (and perhaps inflammation) are positioned more in the mainstream.5, 6 Further information on the role of liver biopsy and histological analysis in specific liver diseases is highlighted below and in published AASLD guidelines referred to above.44, 46-49 Liver biopsy has long been regarded as an important diagnostic adjunct in the evaluation of abnormal liver tests of unclear etiology—that is, after a thorough history, physical examination, biochemical, serological, and imaging investigation have failed to elucidate a diagnosis. Available data indicate that liver histology will, in a proportion of patients, point to a specific diagnosis51 and lead to a change in patient management.52, 53 In one study, histological findings were examined in 354 patients who underwent liver biopsy to investigate abnormal liver tests; 64% of biopsies revealed an element consistent with NAFLD, while other diagnoses included cryptogenic hepatitis, drug-induced liver injury, primary and secondary biliary cirrhosis, AIH, alcohol-related liver disease, primary sclerosing cholangitis (PSC), hemochromatosis, and amyloid and glycogen storage disease.53 Only 6% of patients had a normal liver biopsy, whereas 26% were found to have some degree of fibrosis and 6% of patients had cirrhosis. Patient management was modified in 18% of patients after liver biopsy, and three families were entered into a screening program for heritable liver disease.53 Thus, it was concluded that the finding of abnormal liver tests in the absence of diagnostic serology may indicate significant liver disease and histological analysis provides meaningful information. Conversely, in another study, asymptomatic adult patients with persistent (≥ 6 months) liver test abnormalities were examined (patients with a strong suspicion for a specific liver disease were excluded).52 In this study of 36 patients, a presumptive diagnosis and a preliminary management plan were documented before liver biopsy; prebiopsy diagnoses included nonalcoholic steatohepatitis (NASH; 24 patients), AIH (3 patients), PBC (2 patients), PSC (2 patients), and others (5 patients). Histological findings after liver biopsy changed the diagnosis in only 14% of cases. Thus, although the liver biopsy appeared to help confirm the diagnosis, biopsy findings infrequently altered the suspected prebiopsy diagnosis, and even more rarely altered management.52 Liver histology may also be helpful in the establishment of an unsuspected diagnosis, such as alcoholic liver disease.54, 55 Particularly in the setting of abnormal liver tests of unclear etiology, the risks and benefits of a liver biopsy should be carefully weighed, and the decision to perform a liver biopsy must be individualized. Cryptogenic cirrhosis or cirrhosis of unknown etiology is found to be the assigned diagnosis in 3%–30% of patients with cirrhosis.56, 57 Cryptogenic cirrhosis has several putative causes including NASH, silent or "burnt out" AIH, occult viral infection, and covert alcoholism. Based on well-documented serial biopsy reports demonstrating progression of prior histological NASH to cirrhosis without any continuing definitive evidence of NASH58-60 and based on extensive epidemiological data, NASH is considered one of the leading causes of cryptogenic cirrhosis in many western countries,61-63 although autoimmune disease appears to be a more common underlying disease in some parts of Europe.64, 65 Classification schemes for cryptogenic cirrhosis have been proposed on the basis of the clinical setting and on so-called residual histological findings such as foci of autoimmune-like inflammatory infiltrates versus NASH-like foci of steatosis, cellular ballooning, and glycogenated nuclei.66, 67 Indeed, a recent serial biopsy study of patients with cirrhosis who had antecedent biopsies revealing NASH support the use of these parameters as markers for prior NASH.68 Assessment of liver histology following orthotopic liver transplantation is an essential component of management in this patient population. It is often important to make a specific diagnosis in the setting of liver test abnormalities early after transplantation to investigate allograft rejection, preservation or reperfusion injury, drug-induced liver injury, (usually recurrent) viral infection, or bile duct injury. Liver biopsy is also often helpful in the setting of late allograft dysfunction,69 including to investigate the possibility of recurrence of the original disease.70 Some liver transplant programs perform liver biopsy on a protocol basis after transplantation (e.g., annually), even in those patients with normal liver tests, although compelling evidence to support this approach is lacking. In contrast, there is good evidence suggesting that fibrosis progression may be predicted by using liver histology in patients following transplantation.35, 71 In one study, liver histology obtained at 1 year after transplantation in patients with HCV infection allowed identification of patients with rapid fibrosis progression (donor age > 55 years was associated with rapid fibrosis progression and development of cirrhosis).71 In another study, patients with more advanced fibrosis stages had a greater likelihood of clinical decompensation than those with minimal or no fibrosis.35 In addition, histological assessment appears to be critical in evaluation of the donor liver immediately before it is transplanted. Macrovesicular steatosis, (occult) fibrosis, and inflammation have all been associated with poorer graft function after liver transplantation, especially in older recipients and those with chronic HCV liver disease. Some experts have recommended that donor livers with suspicious clinical histories be evaluated by sampling at least two sites.72 Importantly, while liver ultrasound has high specificity for exclusion of steatosis in apparently normal livers, both its sensitivity and negative predictive value are very low, thus limiting its utility in the diagnosis of a fatty liver.73 Liver biopsy and evaluation of hepatic histology in evaluation of healthy living related donors is controversial.74-76 In a study of 144 donor candidates who underwent liver biopsy as part of the pretransplant donor evaluation, 31 (21%) had at least one histological finding precluding liver donation (21 had steatosis and 10 had other diseases, including non–A-D hepatitis in six cases, diffuse granulomatosis in two, schistosomiasis in one, and cryptogenic fibrosis in one).74 Another study found that approximately half of presumably healthy donors had abnormal pathology results, including nearly one-third of patients with fatty changes.76 Thus, some experts believe that preoperative liver biopsy is a necessary component of the evaluation of potential living donors.74, 76 The use of liver biopsy for evaluation of focal liver disease (i.e., a lesion detected by imaging) is highly variable and difficult. Evaluation of focal liver disease is further complicated because lesions may be cystic, solid, or vascular (or combinations thereof) and because there is considerable overlap in the appearance between benign and malignant lesions. Further, use of liver biopsy almost always depends on the specific clinical scenario. For example, evaluation of mass lesions requires consideration of whether the patient has no known underlying liver disease or whether the patient has a known parenchymal liver process. Both categories of patient may require consideration of liver biopsy in establishing the correct diagnosis. Initially, cross-sectional imaging may confirm that the liver has an abnormal contour consistent with cirrhosis, and may demonstrate other features of portal venous hypertension such as splenomegaly and intra-abdominal varices. Moreover, the liver may be enlarged because of the presence of the lesion(s). In patients with underlying liver disease, especially cirrhosis, the overriding concern is with HCC. This diagnosis can be made in patients with a typical lesion (usually > 2 cm in size, with a typical vascular pattern seen with dynamic imaging techniques).77 In patients with smaller lesions, the use of liver biopsy (typically fine-needle aspiration biopsy) is controversial.78, 79 Arguments against biopsy sampling include: (1) sampling error may leave the diagnosis in doubt; (2) HCC recurrence rates after liver transplantation were significantly higher among patients with tumors larger than 3 cm, pathological tumor-node-metastasis (pTNM) I-III stage, Child class B or C cirrhosis, and alpha-fetoprotein >200 ng/mL who underwent biopsy;80 and (3) there appears to be a but risk of of the which the biopsy was (see below Conversely, the presence of HCC significantly the for liver transplantation, leading to the to positive imaging thus, histological may management by these the reported practice For specific recommendations about liver biopsy in patients with suspected HCC, see the AASLD practice guideline review on this of the about liver biopsy in patients with suspected HCC from in therapeutic and the of predictive utility of histological such as the degree of This area is likely to change as new treatment modalities (e.g., and in conjunction with a of HCC which predict Another mass lesion that may develop in the setting of underlying liver disease is Although lesions may in normal livers, this lesion typically in the presence of chronic biliary disease, PSC or a It usually as a lesion the biliary or the hepatic The decision to biopsy such a it is may be by whether is considered or the possibility of liver transplantation the lesion should be enlarged or other may be at the It may not be possible to distinguish primary hepatic tumors from a more common primary lesion or a on the basis of cross-sectional imaging and in which biopsy is also necessary to confirm the diagnosis. The and whether in the or in an setting, may of patients is the recent of one or more focal hepatic lesions in the absence of underlying liver disease. This may after an imaging test to specific or or perhaps after imaging for that may have to do with the hepatic lesions. who do not have parenchymal liver disease and in whom a focal hepatic is will often have one of the abnormalities highlighted in any of these lesions may be or although most are the most common lesions identified in patients without underlying liver disease include benign hepatic lesions, most often but on occasion For the most these should have on cross-sectional imaging modalities such that liver biopsy is For example, a has characteristic on the imaging and often dynamic with computed focal is typically and has a of hepatic are and appear on the of contrast imaging, concern may for thus making biopsy of one or more lesions liver may be associated with by without an primary may be or (typically are of on imaging, and should be to confirm the diagnosis. there is any as to whether the patient has underlying parenchymal disease, biopsy should also be taken from from the The approach to patients with mass lesions will on the overall clinical 6 some of the more common liver lesions, and imaging imaging a critical role in all liver mass lesions, it is that be in with an imaging Liver biopsy should be considered in patients in whom diagnosis is in and when of a specific diagnosis is likely to the management plan Level Liver histology is an important adjunct in the management of patients with known liver disease, particularly in situations information about fibrosis stage may guide the decision to perform liver biopsy in these situations should be to consideration of the risks and benefits of the Level The approach to liver biopsy has changed over the Currently, liver biopsy is typically on an or the patient will have been seen in the or the a about the and risks of liver biopsy will have it is that many patients liver biopsy experience significant about the the following should also be before the (1) by whom and the biopsy will be (2) whether of any may be taken prior to the or will be available immediately (3) what degree of may be and after the and the available that help and/or (4) when the patient may to of and to the and when the result will be and by what this information will be to the and about these are important to of the and in the patient a of including and should be obtained prior to liver to of liver biopsy, patients should be about liver disease and about other than liver biopsy that may also provide diagnostic and prognostic information Level 4. to of liver biopsy, patients must be carefully about the including and should be obtained Level practice includes measurement of the blood including prothrombin normalized in some the time, and/or at a prior to the Some experts a specimen of blood so that blood be made available at in of with previously documented abnormalities in laboratory tests may require these to be to the of biopsy; the will on the specific clinical and However, as highlighted the utility of these tests in risk is and not by the available Moreover, the of more in patients biopsy, such as which are by tests, is although some of patients with cirrhosis appear to have this should be suspected when there is late consistent with initial and premature are to assess the utility of more of such as this test of and imaging reports should be to ensure that (1) no focal lesion exists in the hepatic and (2) that biliary is not of these to an unsuspected (and in as to whether patients should be prior to biopsy, and data to on the best approach are not is evidence that a before liver biopsy may help a or after the Some experts patients to a fatty so as to (and thus presumably the likelihood of the other others have raised the possibility that may increase portal blood and increase the risk of Further, the may in the of a major all recommendations definitive evidence because recommendations than patient immediately after biopsy; see below) have actually However, a
1
Each recommendation is assigned a Class (benefit versus risk) and Level (strength/certainty) of evidence as required by the AASLD Practice Guidelines Committee.
2
Guidance covers liver biopsy use across multiple conditions including AIH, ALF, HBV, HCV, NAFLD, PBC, PSC, and HCC assessment contexts.
3
Recommendations are based on formal literature review, guideline methodology, existing guideline policies, and authors' clinical experience.
4
The document is intended for physicians and emphasizes flexibility versus rigid standards of care, with specific recommendations tied to published evidence.
5
This AASLD position paper provides evidence-supported, flexible recommendations for diagnostic, therapeutic, and preventive aspects of liver biopsy care.

Liver biopsy procedure and histological assessment of liver tissue

Recommendations and guideline-based assessment of indications, diagnostic/therapeutic/preventive applications, evidence grading (Class and Level), and quality of histological evaluation for liver biopsy use across liver diseases

Publication Details
Publication Date
2008-11-20
Journal
Hepatology
Publisher
Lippincott Williams & Wilkins
ISSN
0270-9139
Cited by
2444
Access Type
Author Information
Authors
Don C. Rockey
Stephen Hugh Caldwell
Zachary D Goodman
Rendon C. Nelson
Alastair D. Smith
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%